Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Indaptus Therapeutics, Inc. (INDP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9900+0.0100 (+0.34%)
At close: 04:00PM EDT
2.9800 -0.01 (-0.33%)
After hours: 07:07PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close2.9800
Open2.9050
Bid2.2000 x 800
Ask3.2000 x 900
Day's Range2.9050 - 3.0700
52 Week Range1.8900 - 28.8300
Volume8,668
Avg. Volume489,982
Market Cap24.693M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INDP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Indaptus Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    24 days agoArgus Research
View more
  • GlobeNewswire

    Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update. “We made substantial progress throughout the second quarter, highlighted by

  • GlobeNewswire

    Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

    NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City. A live webcast of the presentation can be accessed on the Investors section of Indaptus’ website. A replay of the webcast will be archived and available following

  • GlobeNewswire

    Indaptus Therapeutics to Present at Jefferies Healthcare Conference

    NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:45 p.m. ET. A live webcast of the presentation can be accessed on the Investors section of Indaptus’ website. A replay of the webcast will be archived and available following the event for approximate

Advertisement
Advertisement